EDBI Pte Ltd has been actively partnering companies transforming healthcare through digitalization, such as our homegrown Biofourmis, which has now received the FDA’s first ever Breakthrough Device designation for a heart failure digital therapeutic. This will bring the company significantly closer to delivering a new model of care to patients worldwide living with heart failure.
The FDA Breakthrough Device programme is created to help bring effective treatment of life-threatening or irreversibly debilitating conditions to market sooner, and BiovitalsHF is a perfect candidate for this programme due to its clinical importance and impact on a condition that is expected to cost $70 billion per year by 2030.
